Amneal and Zambon Biotech Sign an Exclusive Licensing Agreement for IPX203 to Treat Parkinson’s Disease (PD)
Shots:
- Amneal Pharmaceuticals and Zambon Biotech have signed an exclusive licensing agreement for IPX203 (oral), formulation of carbidopa/levodopa (CD/LD) extended-release capsules, in the EU, United Kingdom & Switzerland
- Under the agreement, Zambon will look for the regulatory approval & commercialization of IPX203 in the EU. The companies did not disclose the financial terms
- Additionally, IPX203 is under review with the US FDA for the treatment of Parkinson’s Disease. Knight Therapeutics is responsible for its regulatory approval & commercialization in Canada & Latin America as per an exclusive licensing agreement
Ref: Amneal | Image: Amneal
Related News:- Amneal Receives Complete Response Letter on the NDA for IPX203 to Treat Parkinson’s Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
